REAL-WORLD UTILISATION AND CLINICAL OUTCOMES OF PATIENTS WITH BRCA-MUTATED ADVANCED OVARIAN CANCER TREATED WITH OLAPARIB IN THE FIRST-LINE MAINTENANCE SETTING: 2-YEAR CLINICAL OUTCOMES OF THE PAN-EUROPEAN OVAL-1 STUDY

被引：0

作者：

Lorusso, Domenica ^{[1
,2
]}

Garbay, Delphine ^{[3
]}

Asselain, Bernard Jean Roger ^{[4
]}

Miller, Rowan ^{[5
,6
]}

Raspagliesi, Francesco ^{[7
]}

Zamagni, Claudio ^{[8
]}

Leary, Alexandra ^{[9
]}

Bellier, Charlotte ^{[10
]}

Glasspool, Ros ^{[11
,12
]}

Jayson, Gordon ^{[13
,14
]}

Grevat, Emmanuelle ^{[15
]}

Kertous, Mehdi ^{[15
]}

Sabatucci, Ilaria ^{[16
]}

Padrone, Claudia ^{[16
]}

Jayia, Parveen ^{[17
]}

Hada, Manila ^{[18
]}

Mclaurin, Kimmie ^{[18
]}

Gourley, Charlie ^{[19
]}

机构：

[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Dipartimento Scienze Salute Donna, Bambino & Sanita Pubbl, Rome, Italy

[2] Univ Cattolica Sacro Cuore, Rome, Italy

[3] Clin Tivoli Ducos, Bordeaux, France

[4] ARCAGY GINECO, Paris, France

[5] Univ Coll London Hosp, London, England

[6] St Bartholomews Hosp, London, England

[7] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[8] IRCCS Azienda Osped Univ Bologna, Bologna, Italy

[9] Inst Gustave Roussy, Villejuif, France

[10] Ctr Oscar Lambret, Dept Cancerol Gynecol & Senol, Lille, France

[11] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Scotland

[12] Univ Glasgow, Glasgow, Scotland

[13] Univ Manchester, Dept Med Oncol, Christie NHS Fdn Trust, Manchester, England

[14] Univ Manchester, Div Canc Sci, Fac Biol Med & Hlth, Manchester, England

[15] AstraZeneca, Paris, France

[16] AstraZeneca, Milan, Italy

[17] AstraZeneca, London, England

[18] AstraZeneca, Oncol Outcomes Res, Global Med Affairs Evidence Generat & External Al, Gaithersburg, MD USA

[19] Univ Edinburgh, Canc Res UK Scotland Ctr, Edinburgh, Scotland

来源：

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2023年 / 33卷

关键词：

D O I：

10.1136/ijgc-2023-ESGO.895

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

512

引用

页码：A426 / A426

页数：1

共 50 条

[21] Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Balmana, Judith
Fasching, Peter A.
Couch, Fergus J.
Delaloge, Suzette
Labidi-Galy, Intidhar
O'Shaughnessy, Joyce
Park, Yeon Hee
Eisen, Andrea F.
You, Benoit
Bourgeois, Hughes
Goncalves, Anthony
Kemp, Zoe
Swampillai, Angela
Jankowski, Tomasz
Sohn, Joo Hyuk
Poddubskaya, Elena
Mukhametshina, Guzel
Aksoy, Sercan
Timcheva, Constanta V.
Park-Simon, Tjoung-Won
Anton-Torres, Antonio
John, Ellie
Baria, Katherine
Gibson, Isabel
Gelmon, Karen A.
Koynova, Tatyana
Popov, Vasil
Timcheva, Constanta
Tomova, Antoaneta
Eisen, Andrea
Gelmon, Karen
Lemieux, Julie
Augereau, Paule
Bazan, Fernando
Becuwe, Celia
Bourgeois, Hugues
Chakiba, Camille
Chehimi, Mohamad
Cheneau, Caroline
Dalenc, Florence
de Guillebon, Eleonore
de la Motte Rouge, Thibault
Frenel, Jean-Sebastien
Goncalves, Anthony
Grenier, Julien
Hardy-Bessard, Anne Claire
Lamy, Regine
Levy, Christelle
Lortholary, Alain
Mailliez, Audrey
BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (02) : 237 - 248
[22] SAFETY OUTCOMES OF OLAPARIB AS MAINTENANCE THERAPY FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH BRCA-MUTATED METASTATIC PANCREATIC CANCER: RESULTS FROM THE POLO STUDY
Van Kuiken, Katelyn
Golan, Talia
Cui, Karen
Brickel, Neil
Gupta, Charu
Kindler, Hedy
ONCOLOGY NURSING FORUM, 2022, 49 (02) : E61 - E62
[23] Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
Zimmerman Savill, Kristin M.
Ivanova, Jasmina
Asgarisabet, Parisa
Falkenstein, Angelica
Balanean, Alexandrina
Niyazov, Alexander
Ryan, Joanne C.
Kish, Jonathan
Gajra, Ajeet
Mahtani, Reshma L.
ONCOLOGIST, 2023, 28 (05): : 414 - 424
[24] Real-world data of PARP inhibitors in first-line maintenance for BRCA mutated or HRD positive advanced ovarian cancer: A multicenter retrospective study from India
Kumar, Y. S.
Panda, S. S.
Moharana, L.
Samantaray, L.
Saju, S. V.
Rathnam, K. K.
Raju, H. S.
Sehrawat, A.
Sundriyal, D.
Kingsley, P. A.
Priya, K. B.
Kayal, S.
Dubashi, B.
Philips, A. O.
Cyriac, S. L.
Natarajan, S.
Mohanty, S. S.
Ganesan, P.
ANNALS OF ONCOLOGY, 2024, 35 : S1552 - S1552
[25] Impact of radiological disease progression on the health status of patients (pts) with BRCA-mutated advanced ovarian cancer (OC) treated with maintenance olaparib (OL) or placebo (PL) after first-line platinum chemotherapy
Friedlander, M. L.
Hettle, R.
Parkhomenko, E.
ANNALS OF ONCOLOGY, 2019, 30
[26] Real-world data of olaparib maintenance therapy in patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer: Final results of the C-PATROL study
Marme, F.
Hilpert, F.
Welslau, M.
Grabowski, J. P.
Schneeweiss, A.
Hartkopf, A. D.
Becker, S.
Runnebaum, I.
Bauerschlag, D.
Fasching, P.
Brandi, C.
Rehbein, J-K.
Glowik, R.
Sehouli, J.
ANNALS OF ONCOLOGY, 2023, 34 : S535 - S536
[27] US real-world immunotherapy-based treatment patterns and clinical outcomes of advanced NSCLC (aNSCLC) patients in the first-line setting
Bittoni, M. A.
Divan, H. A.
Krishna, A.
Gosset, S.
Carbone, D. P.
ANNALS OF ONCOLOGY, 2021, 32 : S1416 - S1416
[28] A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice
Viray, Hollis
Piper-Vallillo, Andrew J.
Widick, Page
Academia, Emmeline
Shea, Meghan
Rangachari, Deepa
VanderLaan, Paul A.
Kobayashi, Susumu S.
Costa, Daniel B.
CANCERS, 2024, 16 (06)
[29] Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
Umpawan, N.
Termsinsuk, P.
Kaosombatwattana, U.
Akewanlop, C.
Korphaisarn, K.
ANNALS OF ONCOLOGY, 2023, 34 : S919 - S920
[30] Real-world clinical outcomes in BRCA-positive metastatic breast cancer patients treated in the community oncology setting
Houts, Arthur C.
Olufade, Temitope O.
Shenolikar, Rahul
Walker, Mark S.
CANCER RESEARCH, 2018, 78 (04)

← 1 2 3 4 5 →